Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011.

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

Author information

1
University of Colorado Cancer Center.
2
Moffitt Cancer Center.
3
Huntsman Cancer Institute at the University of Utah.
4
Patient Advocate.
5
Mayo Clinic Cancer Center.
6
Stanford Cancer Institute.
7
Vanderbilt-Ingram Cancer Center.
8
University of Wisconsin Carbone Cancer Center.
9
Massachusetts General Hospital Cancer Center.
10
UCSF Helen Diller Family Comprehensive Cancer Center.
11
Fox Chase Cancer Center.
12
Roswell Park Comprehensive Cancer Center.
13
Abramson Cancer Center at the University of Pennsylvania.
14
Memorial Sloan Kettering Cancer Center.
15
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
16
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
17
Duke Cancer Institute.
18
University of Michigan Rogel Cancer Center.
19
UC San Diego Moores Cancer Center.
20
Fred & Pamela Buffett Cancer Center.
21
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
22
O'Neal Comprehensive Cancer Center at UAB.
23
City of Hope National Medical Center.
24
St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.
25
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
26
Dana-Farber/Brigham and Women's Cancer Center.
27
The University of Texas MD Anderson Cancer Center.
28
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; and.
29
National Comprehensive Cancer Network.

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non-muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.

PMID:
32135513
DOI:
10.6004/jnccn.2020.0011

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center